gdc
FDA NewsLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Recommended For You
CONQUER CamLeukemiaPatient Stories
CONQUER Cam: A Spotlight on Joyce Beecher
Joyce Beecher vividly recounts her cancer journey as a caregiver to her husband, Rich Beecher, who was diagnosed with chronic lymphocytic leukemia (CLL) in 2003. Listen to Joyce’s story as she describes their determination to find the best care and treatment for Rich, and encourages patients and caregivers to never give up.
CONQUER CamLeukemiaPatient Stories
CONQUER Cam: A Spotlight on Rich Beecher
Diagnosed in 2003, Rich Beecher has been living with chronic lymphocytic leukemia (CLL) for 15 years. Rich describes his cancer journey – from “Why me?” to focusing on the positive things in his life, including immersing himself more in photography.
Leukemia
Exciting Advances in the Treatment of Patients with Chronic Lymphocytic Leukemia
By Kristen Chanley
New therapies that are now available for people with this type of cancer have fewer side effects than traditional chemotherapy and can improve survival and quality of life.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country